Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 1, 2011 | Post-IPO Debt | — | 1 | — | — | Detail |
Aug 14, 2008 | Series Unknown | $19M | 1 | Caxton Advantage Life Sciences Fund | — | Detail |
Sep 13, 2006 | Series Unknown | $36M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Caxton Advantage Life Sciences Fund | Yes | Series Unknown |
Hercules Capital | — | Post-IPO Debt |
SIM Equity | — | Series Unknown |
Sears Capital Management | — | Series Unknown |